It has been reported that minor stroke patients who are LoFA carriers show a reduced response to clopidogrel, and lower levels of clopidogrel active metabolites have been found in patients carrying CYP2C19 LoFAs [6, 33]. This evidence concerns the gene CYP2C19 and Stroke.